Biocept reports third quarter 2021 financial results

San diego--(business wire)--biocept, inc. (nasdaq: bioc), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended september 30, 2021 and provides a business update. “with cnside, our paradigm-changing neuro-oncology test that uses cerebrospinal fluid for diagnosing and monitoring patients with brain metastases, we are reporting strong sequential quarter volume growth, primarily driven by data generated with our acad
BIOC Ratings Summary
BIOC Quant Ranking